VeonGen develops next-generation gene therapies primarily for ophthalmic diseases with high unmet medical need. The company utilizes proprietary vector platforms, including vgAAV and vgRNA REVeRT, to overcome limitations of traditional AAV therapies for superior delivery and large gene expression. These platforms enable less invasive administration routes and the modulation of multiple genes for therapeutic effect.
Funding
$16.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic disorders lack effective treatments due to the challenge of delivering therapeutic genes precisely and efficiently to the affected cells or tissues. Traditional gene therapy approaches may suffer from off-target effects or limited transduction efficiency, hindering their clinical potential.
Solution
ViGeneron is developing adeno-associated virus (AAV) vectors optimized for targeted gene delivery, aiming to improve the treatment of genetic disorders. Their technology focuses on engineering AAV capsids to enhance tissue specificity and transduction efficiency, thereby minimizing off-target effects and maximizing therapeutic impact. By precisely modifying genes at the molecular level, ViGeneron seeks to address previously untreatable conditions and improve patient outcomes. The company's approach aims to overcome the limitations of conventional gene therapy by enabling more selective and effective gene transfer.
Target Audience
ViGeneron's primary focus is on patients with genetic disorders and the clinicians who treat them, as well as pharmaceutical companies seeking advanced gene therapy solutions.
Features
- AAV vector engineering for enhanced tissue specificity
- Optimized capsids for improved transduction efficiency
- Targeted gene delivery to minimize off-target effects